Phase Genomics CEO Ivan Liachko. (Phase Genomics Photo)
Seattle biotech company Phase Genomics announced Wednesday that it received two National Institutes of Health (NIH) grants totaling $3.9 million. The funding, which runs for three years, will help pay for projects focused on chromosomal abnormalities that cause problems with fertility and reproduction and with diseases such as cancer.
Many peopleRead entire article on